RxDoctor Payments Data

Sandra Reed, NP

Family · Taylorsville, NCNPI 1194319806

Payments from drug & device makers

$9,663in general payments, 2019–2025

Across 473 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$1K
  • Bayer$885
  • AstraZeneca$826
  • Otsuka America Pharmaceutical, Inc.$492
  • ANI Pharmaceuticals, Inc.$429
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$9,625100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,663 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,238
Medicare patients
38
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase70$2,370,582
OzempicSemaglutide74$79,492
FarxigaDapagliflozin Propanediol53$37,259
VraylarCariprazine Hcl19$30,204
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$28,933
EliquisApixaban28$26,014
MounjaroTirzepatide25$25,382
VascepaIcosapent Ethyl33$19,223
Tresiba Flextouch U-200Insulin Degludec24$15,069
Soliqua 100-33Insulin Glargine/Lixisenatide19$13,456
JardianceEmpagliflozin11$11,467
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,913
VeozahFezolinetant13$6,674
Dexlansoprazole DrDexlansoprazole11$2,348
Albuterol Sulfate HfaAlbuterol Sulfate54$1,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$2,500$2,370,58270 claims
Novo NordiskOzempic$297$79,49274 claims
AstraZenecaFarxiga, Breztri Aerosphere$826$47,17367 claims
AbbVieVraylar$1,134$30,20419 claims
GSKTrelegy Ellipta$226$28,93344 claims
PfizerEliquis$332$26,01428 claims
Lilly USA, LLCMounjaro$197$25,38225 claims
Boehringer IngelheimJardiance$82$11,46711 claims
Astellas Pharma US IncVeozah$85$6,67413 claims
ANI Pharmaceuticals, Inc.Valsartan$429$23213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Taylorsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →